Puma Biotechnology (PBYI) Short term Debt (2019 - 2026)

Puma Biotechnology's Short term Debt history runs 7 years deep, the most recent figure standing at $11.3 million for Q1 2026.

• Quarterly Short term Debt fell 75.11% year-over-year to $11.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.3 million (down 75.11% YoY) and the FY2025 annual result came in at $22.5 million, down 50.31% from the prior year.
• Short term Debt was $11.3 million for Q1 2026 at Puma Biotechnology, down from $22.5 million in the prior quarter.
• Across five years, Short term Debt topped out at $45.3 million in Q1 2024 and bottomed at $11.3 million in Q1 2026.
• A 4-year average of $33.0 million and a median of $34.0 million in 2023 frame the typical range for Short term Debt.
• Annual changes were most pronounced in 2024 — Short term Debt jumped 300.01% — and 2026, when it slumped 75.11%.
• Puma Biotechnology's Short term Debt stood at $34.0 million in 2023, then jumped by 33.33% to $45.3 million in 2024, then slumped by 50.31% to $22.5 million in 2025, then sank by 49.9% to $11.3 million in 2026.
• Business Quant data shows PBYI's Short term Debt at $11.3 million in Q1 2026, $22.5 million in Q4 2025, and $33.7 million in Q3 2025.